Sort By

Sep 9, 2014

OrbiMed Advisors Raises $325M for Second Asia Health-Care Fund

Feb 2, 2015

OrbiMed Launches $924 Million Royalty Credit Opportunities Fund

Apr 29, 2015

Betting on China for new Drug Dev BrandVoice

Dec 17, 2015

The Year's Best VC Deal Was for a Company You've Never Heard Of

Dec 21, 2015

OrbiMed Launches $950 Million Venture Capital Fund

Mar 15, 2016

OrbiMed Advisors Offers 'One-Stop Shop' for Health-Care Companies

May 23, 2016

OrbiMed doubles down on Israeli biotechs with $307M fund

May 23, 2016

OrbiMed Launches $307 Million Israel Venture Capital Fund

Aug 29, 2016

Cancer Upstart CBT closed $9.7M Series A; OrbiMed Lead Investor

Sep 19, 2016

OrbiMed Portfolio Companies Adicet Bio and Rhythm Pharma Ranked In Fierce 15

Feb 2, 2017

OrbiMed Comments on Immunomedics Proxy Contest

Feb 28, 2017

OrbiMed Logs Two Decades of Novel Attacks on Cancer

Sep 5, 2017

OrbiMed Launches $551 Million Asia Private Equity Fund

Sep 25, 2017

In a First, Pfizer Spins Out Biotech Firm with $103 Million in Funding

Sep 26, 2017

OrbiMed Invests $42.5mm in ViviMed

Feb 26, 2018

OrbiMed Named Among Most Active European Life Sciences Investors

Apr 3, 2018

Carl Gordon named to 2018 Forbes Midas List

Apr 3, 2018

Jonathan Silverstein named to 2018 Forbes Midas List

Apr 27, 2018

OrbiMed Announces Completion of Leadership Transition

May 9, 2018

OrbiMed Announces New General Partner

Jun 18, 2018

China's Market is a "Once-in-a-Lifetime Opportunity"

Dec 11, 2018

OrbiMed's Nash Terns

Feb 14, 2019

Passage Bio Founded With $116 million financing, led by OrbiMed

Apr 2, 2019

Carl Gordon named to 2019 Forbes Midas List

Jun 18, 2019

OrbiMed Comments on Takeda Pharmaceuticals Proxy

Our professional values trump net present values any day. OrbiMed is a collegial culture, working together for over 25 years in a collaborative, diverse, team-oriented environment.